Treating hepatitis C in methadone maintenance patients: an interim analysis (Q44049000)

29 November 2017

Treating hepatitis C in methadone maintenance patients: an interim analysis (English)

1 reference

29 November 2017

1 reference

Diana L Sylvestre

1

1 reference

29 November 2017

1 July 2002

1 reference

Drug and Alcohol Dependence

29 November 2017

1 reference

29 November 2017

67

1 reference

29 November 2017

2

1 reference

29 November 2017

117-123

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

29 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Treatment of chronic hepatitis C in active drug users.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Antibody to Hepatitis C Virus among Cardiac Surgery Patients, Homosexual Men, and Intravenous Drug Users in Baltimore, Maryland

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Hepatitis C virus antibodies among risk groups in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Sharing of drug preparation equipment as a risk factor for hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Hepatitis C virus infection in Chicago women with or at risk for HIV infection: evidence for sexual transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Hepatitis C in methadone maintenance patients: prevalence and public policy implications

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Paroxetine for the prevention of depression induced by high-dose interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Assessing depressive symptoms in five psychiatric populations: a validation study

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900010-8

7 January 2021

10.1016/S0376-8716(02)00010-8

Identifiers

DOI

1 reference

29 November 2017

1 reference

PubMed ID

12095661